Rebuilding FNIH’s Approach to Patient Engagement as a Core Part of the Organization

Julie Gerberding, MD, joined the FNIH as CEO on May 16, 2022. She served before that as chief Patient Officer and Executive Vice President, Population Health & Sustainability, at Merck & Co, Inc. She was responsible for patient engagement, corporate social responsibility, Environmental/Social/Governance issues, and other functions. Formerly, Dr Gerberding oversaw Global Public Policy and Strategic Communications for the company. She joined Merck in 2010 as President of Merck Vaccines and was instrumental in increasing access to the company’s vaccines to people around the world.